Hepatitis B and C infection in patients undergoing biologic and targeted therapies for rheumatic diseases
Copyright © 2019 Elsevier Ltd. All rights reserved..
Hepatitis B and C are common viral infections that affect more than 430 million population worldwide. In patients with rheumatic diseases, the prevalence of inactive/chronic hepatitis B infection ranges from 0.4% to 38% and that of past/resolved infection is much higher (7.3%-69%). The prevalence of hepatitis C infection in rheumatic disorders is less clear but probably lower than that of hepatitis B (1.7%-4%). With the increasing use of biologic and targeted disease-modifying antirheumatic drug therapies, reactivation of past and chronic hepatitis B and C infection is increasingly recognized, with presentation ranging from asymptomatic viremia to serious clinical hepatitis with liver failure. The concomitant use of effective antiviral therapies helps reduce the risk of hepatitis B reactivation and control of active hepatitis C infection. This article summarizes the prevalence and risk factors of hepatitis B and C reactivation in patients with rheumatic diseases undergoing biologic and targeted therapies, as well as the recommendations for screening, monitoring, and treatment of these infections.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Best practice & research. Clinical rheumatology - 32(2018), 6 vom: 21. Dez., Seite 767-780 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mok, Chi Chiu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biological |
|---|
| Anmerkungen: |
Date Completed 12.11.2019 Date Revised 12.11.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.berh.2019.03.008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM30037061X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM30037061X | ||
| 003 | DE-627 | ||
| 005 | 20231225102359.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.berh.2019.03.008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1001.xml |
| 035 | |a (DE-627)NLM30037061X | ||
| 035 | |a (NLM)31427054 | ||
| 035 | |a (PII)S1521-6942(19)30043-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mok, Chi Chiu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hepatitis B and C infection in patients undergoing biologic and targeted therapies for rheumatic diseases |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.11.2019 | ||
| 500 | |a Date Revised 12.11.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Hepatitis B and C are common viral infections that affect more than 430 million population worldwide. In patients with rheumatic diseases, the prevalence of inactive/chronic hepatitis B infection ranges from 0.4% to 38% and that of past/resolved infection is much higher (7.3%-69%). The prevalence of hepatitis C infection in rheumatic disorders is less clear but probably lower than that of hepatitis B (1.7%-4%). With the increasing use of biologic and targeted disease-modifying antirheumatic drug therapies, reactivation of past and chronic hepatitis B and C infection is increasingly recognized, with presentation ranging from asymptomatic viremia to serious clinical hepatitis with liver failure. The concomitant use of effective antiviral therapies helps reduce the risk of hepatitis B reactivation and control of active hepatitis C infection. This article summarizes the prevalence and risk factors of hepatitis B and C reactivation in patients with rheumatic diseases undergoing biologic and targeted therapies, as well as the recommendations for screening, monitoring, and treatment of these infections | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Biological | |
| 650 | 4 | |a DMARD | |
| 650 | 4 | |a Hepatitis | |
| 650 | 4 | |a Pre-emptive | |
| 650 | 4 | |a Reactivation | |
| 650 | 4 | |a Targeted | |
| 773 | 0 | 8 | |i Enthalten in |t Best practice & research. Clinical rheumatology |d 2001 |g 32(2018), 6 vom: 21. Dez., Seite 767-780 |w (DE-627)NLM112644929 |x 1532-1770 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2018 |g number:6 |g day:21 |g month:12 |g pages:767-780 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.berh.2019.03.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2018 |e 6 |b 21 |c 12 |h 767-780 | ||